Daniel Vogel

Genomics plc is a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. Genomics plc uses large-scale genetic information to realise precision healthcare and improve drug discovery. Genomics plc is leading the new area of genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for common diseases, well ahead of disease manifestation, allowing targeted interventions and tailored screening to prevent disease entirely, or to catch it early when outcomes remain favourable. Genomics plc’s population health management services and clinical decision support tools bring greater, earlier and more accurate understanding about individual risk for all of the common chronic diseases and cancers to doctors and their patients. The company also uses insights from genomic variation to accelerate the discovery and development of new medicines. Backed by some of the leading investors in life sciences, the Genomics plc team is a multi- disciplinary group of scientists, engineers and deployment specialists focused on turning world- leading science into powerful and widely applied healthcare solutions, offering the chance of transforming lives around the world. Headquartered in Oxford, Genomics plc also has offices in Cambridge (UK) and Boston (US). For additional information about Genomics plc, please visit www.genomicsplc.com.